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 Abstract  
We analyzed changes in hepatitis B virus (HBV) and hepatitis delta virus (HDV) viral loads 
during tenofovir-containing antiretroviral therapy among patients with a replicating HDV 
infection in the Swiss HIV Cohort Study. Only 28.6% experienced a ≥2.0 log reduction in 
HDV RNA and 14.3% had undetectable HDV viral load within five years.  
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Introduction  
In HIV infected patients, hepatitis delta virus (HDV) coinfection is associated with a higher 
incidence of hepatic flares and decompensation, an increased incidence of hepatocellular 
carcinoma (HCC), as well as higher mortality(1-3). In the Swiss HIV Cohort Study (SHCS), 
HDV-infected patients were eight times more likely to die from liver-related complications 
than HDV-uninfected ones(4). Currently, pegylated interferon (IFN) alpha remains the 
mainstay of HDV therapy, despite its limited success(5-7). The addition of nucleos(t)ide 
reverse transcriptase inhibitors (NRTIs) to IFN did not improve virological outcomes in large 
trials(8-10). The impact of long-term treatment with NRTIs on HDV suppression in 
HIV/hepatitis B virus (HBV)-coinfected patients has been a matter of debate. While Soriano 
et al. showed a reduction in HDV replication and liver stiffness after a median of 4.8 years of 
TDF-containing antiretroviral therapy (ART) in HIV/HBV-coinfected individuals in Spain(11), 
Boyd et al. failed to show a similar impact of TDF  in a French cohort(12). As TDF is now 
available as a component of first-line ART throughout the world, more data are needed on its 
impact on long-term virological outcomes. We assessed the impact of long-term TDF therapy 
on HBV and HDV replication in a nationwide HIV cohort. 
 
Patients and methods 
All SHCS (www.shcs.ch) participants with a positive HBsAg test between January 1988 and 
December 2014 were considered(13). HDV serology was assessed in all patients as 
described before(4). For this analysis, we included all patients with an HDV RNA >300 cp/ml 
at TDF initiation and who had a follow-up sample after at least one year of TDF. All routine 
data were collected prospectively within the framework of the SHCS. Local Ethical 
Committees of all participating study sites have approved the study and written consent has 
been obtained from all participants. 
For HDV amplification, total nucleic acids were purified from 200 µl plasma (Qiagen EZ1 
DSP kit), and cDNA (High Capacity cDNA Reverse Transcription Kit, Applied BiosystemsTM) 
 was subjected to real-time polymerase chain reaction (PCR) according to Ferns et al(14). 
HDV genotype was assessed by sequencing and phylogenetic analysis of a 260-base-pair 
cDNA fragment encompassing the 3’ end of the hepatitis D antigen coding region. HBV DNA 
was quantified using the COBAS AmpliPrep/TaqMan48 system (Roche Diagnostics 
International AG, Switzerland). HBV genotyping was performed by PCR Amplification, 
Sanger sequencing and subsequent in silico analysis by the geno2pheno tool 
(http://hbv.geno2pheno.org/index.php) as described previously(15). HBV suppression was 
defined as HBV DNA<20 IU/ml and low-level viremia as HBV DNA 20-2000 IU/ml. 
Quantitative HBsAg (qHBsAg) was analyzed with a fully automated chemiluminescent 
microparticle immunoassay (Architect, Abbott Diagnostics, USA).  
Demographic and clinical characteristics at TDF start were described using absolute 
numbers and proportions, or medians and interquartile ranges (IQR). Individual follow-up 
started at initiation of TDF and ended on the date of death, loss to follow-up, TDF interruption 
or  database closure (31.12.2014), whichever happened first. The proportion of patients 
reaching HDV RNA suppression or experiencing a viral load drop ≥2 log were described and 
their main characteristics compared with those of the other patients using Fisher’s exact and 
Mann-Whitney tests. Changes in HBV DNA and qHBsAg levels were also described. 
Statistical analyses were performed using Stata Version 13.1. 
 
Results 
Study population 
Of 73 patients with replicating HDV in the SHCS, 34 (46%) had been on TDF for more than a 
year and follow-up samples were available in 21 of them. At baseline, patients were 
predominantly middle-aged (median: 40 years [IQR 35-45]) males (19/21 [90.5%]) from 
north-western Europe (15/21 [71.4%]). Only 2/21 (9.5%) patients were from sub-Saharan 
Africa (Supplementary Table). Thirteen of the 21 (61.9%) were persons who currently or 
previously injected drugs (PWID). Most individuals had already been on another ART 
regimen at time of TDF start (80.9%) for a median of 6.3 years and 70.6% of them had a 
suppressed HIV viral load. Prior lamivudine treatment was present in 8/21 (38.1%) patients. 
Two thirds had a CD4 count < 350 cells/µl. At TDF start, one half of the patients had either 
suppressed (5/21, 23.8%) or low-level (6/21, 28.6%) HBV DNA. Of 11 patients with available 
results from HBV sequencing, 8 were infected with genotype D and 3 with genotype A. All 
patients were infected with HDV genotype 1. Median qHBsAg was 3.9 log10 IU/ml (IQR 3.4-
4.1). Two-thirds had a positive anti-HCV serology (66.7%) whereas only 2/21 (9.5%) patients 
had detectable HCV RNA. Transaminases were elevated [ACTG (AIDS Clinical Trials Group) 
grade 1-4] in 15/21 (75%) of the patients. 
 
 HBV and HDV follow-up parameters 
Patients were followed for a median of 4.9 years (IQR 2.4-7.7) on TDF. Two of the 21 
patients died during follow-up, one from HCC and one from decompensated cirrhosis, and no 
patients were lost to follow-up. Median HDV RNA was 7.0 log10 cp/ml (IQR 5.7-8.1) before 
TDF initiation and 6.7 log10 cp/ml (IQR 4.6-7.2) at the last follow-up visit (Figure). Sixteen of 
the 21 patients (76%) reached HBV suppression (<20 IU/ml) after a median of 2.9 years (IQR 
2.0-3.1) and the 5 remaining patients had low-level viremia. qHBsAg was 3.9 log10 IU/ml at 
TDF initiation and 3.6 log10 IU/ml (IQR 3.1-3.9) at the last follow-up visit. Six (28.6%) patients 
experienced >2 log10 HDV RNA reduction during follow-up, and HDV RNA became 
undetectable in three of them (14.3%). No differences in HBV DNA levels, qHBsAg, liver 
enzymes or HIV-1 related characteristics were noted between individuals with and without 
HDV RNA reduction during TDF treatment. These six patients were all men, were slightly 
younger (37 years [IQR 35-40] vs. 43 [IQR 36-46]), had a lower baseline HDV RNA (5.8 [IQR 
3.2-7.7] log10 cp/ml vs. 7.3 [IQR 5.9-8.1]) and were less likely to be on an HBV-active 
treatment at TDF start (1/6 [16.7%] vs. 7/15 [46.7%]), but none of these results were 
statistically significant. The 3 patients who achieved HDV suppression during follow-up had 
lower HDV RNA (3.2 [IQR 3.1-5.5] log10 cp/ml vs. 7.4 [IQR 6.0-8.1], p=0.01) and lower 
qHBsAg (2.1 [IQR -0.7-3.5] log10 cp/ml vs. 4.0 [IQR 3.8-4.1], p=0.02) at baseline and none 
of them was pre-treated with an HBV-active drug. HBsAg loss was only observed in one 
patient who initiated TDF with a very low baseline qHBsAg.  
 
Discussion 
Among 21 HIV/HBV-coinfected individuals with a replicating HDV infection at TDF initiation, 
only a minority experienced a reduction of at least 2 log in HDV viral load during a median of 
5 years of therapy and only three individuals reached HDV RNA suppression despite 
successful HBV therapy. In most patients, TDF therapy was not associated with a decrease 
in HDV RNA levels, which underlines the need for alternative therapies in order to control 
HDV in this population at high risk of liver-related events. 
In line with the results from a cohort of 17 patients in France we found that HDV RNA 
decreased minimally during TDF treatment, and that only a minority of patients achieved full 
HDV suppression(12).  Our results contrast with the findings from a Spanish cohort in which 
HDV RNA dropped significantly in all 19 participants after a median time of 54 months(11). 
The main reasons for these differences across studies cannot be explained by major 
differences in demographic and HIV-related characteristics. In all three studies, 
concentrations of HBsAg seemed not to be affected by TDF (11, 12, 16). Despite the limited 
success of TDF in treating HDV infection, positive outcomes seem to be possible in selected 
individuals, as reported previously in HIV-uninfected individuals (17, 18). We recently 
 reported the case of an HIV/HBV/HDV-coinfected patient with an uncontrolled hepatitis delta 
after initial suppression on TDF (19). In this case, the observation that initial HDV 
suppression was achieved when the patient had a low CD4 cell count pointed towards a 
potential role of immunological recovery in the suppression of HDV infection. In the present 
study, the three patients who achieved HDV suppression did not have a severe impairment 
of cellular immunity but had lower HDV-RNA and qHBsAg at baseline compared to the other 
patients. Interestingly, they were not treated with HBV-active drugs before TDF initiation and 
might have benefitted from the initial impact on HBV infection from this drug. It is uncertain if 
these patients would have cleared HDV without TDF treatment.  
We studied the impact of TDF on HDV replication in a nationwide cohort of HIV/HBV-
coinfected individuals. Detailed virological analyses allowed the thorough assessment of the 
long-term impact of TDF-containing ART on HDV outcomes. Unfortunately we did not have 
data on liver fibrosis at different time-points for most patients, which limited the robustness of 
our results regarding clinical outcomes. Furthermore, 13 patients had to be excluded from 
our analyses because they did not have a stored serum or plasma sample available, or were 
lost to follow-up. 
In conclusion, TDF is highly efficient in suppressing HIV and HBV replication in patients 
coinfected with HDV. However, in the majority of these patients TDF did not result in a 
reduction of HDV RNA or qHBsAg. As replicating HDV infection is strongly associated with 
liver-related mortality, there is an urgent need for new treatment options. 
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 Figure:  
Hepatitis D virus (HDV) RNA, Hepatitis B virus (HBV) DNA, quantitativ Hepatitis B surface 
antigen (HBsAg) and alanine aminotransferase (ALT) trajectories during tenofovir (TDF)-
containing ART 
 
